Molecular response and quality of life in chronic myeloid leukemia patients treated with intermittent TKIs: First interim analysis of OPTkIMA study.
Michele MalagolaAlessandra IurloElisabetta AbruzzeseMassimiliano BonifacioFabio StagnoGianni BinottoMariella D'AddaMonia LunghiMonica CrugnolaMaria Luisa FerrariFrancesca LunghiFausto CastagnettiGianantonio RostiRoberto M LemoliRosaria SancettaMaria Rosaria CoppiMaria Teresa CorsettiGiovanna Rege CambrinAtelda RomanoMario TiribelliAntonella Russo RossiSabina RussoLara AprileMonica BocchiaLisa GandolfiMirko FarinaSimona BernardiNicola PolverelliAldo M RoccaroAntonio De VivoMichele BaccaraniDomenico RussoPublished in: Cancer medicine (2021)
De-escalation of any TKI by 1 month ON/OFF schedule maintains the MR3.0 /MR4.0 in 81% of the patients during the first 12-24 months. No patients progressed to accelerated/blastic phase, all the patients (23.5%) losing MR3.0 regained the MR3.0 and none suffered from TKI withdrawn syndrome. The study firstly report on HRQoL in elderly CML patients moving from a continuous daily therapy to a de-escalated intermittent treatment.
Keyphrases
- end stage renal disease
- ejection fraction
- newly diagnosed
- chronic kidney disease
- prognostic factors
- magnetic resonance imaging
- stem cells
- randomized controlled trial
- clinical trial
- chronic myeloid leukemia
- mesenchymal stem cells
- advanced non small cell lung cancer
- case report
- epidermal growth factor receptor
- single molecule
- cell therapy
- smoking cessation
- replacement therapy
- chemotherapy induced